# Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus

Source: https://onco.cc/trials/nct02971345/  
OnCo record `nct02971345` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Epirubicin and Ethiodized oil in Hepatocellular carcinoma, run by Shanghai Zhongshan Hospital, with a status the registry has not verified recently.

## Summary

Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus is a phase 3 interventional study registered as NCT02971345 by Shanghai Zhongshan Hospital, with 253 participants planned, started 2017-01 and due to reach its primary completion in 2020-10. Interventions recorded: Stent and Iodine-125 seed strand implantation, Stent, Iodine-125 seed, Epirubicin, Ultra-fluid lipiodol, Gelatin sponge articles. Conditions recorded: Hepatocellular Carcinoma, Portal Vein Tumor Thrombus.

Linked to the drug Ethiodized oil because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02971345
- Phase: 3
- Setting: Endovascular Brachytherapy Combined With Stent Placement and Transcatheter Arterial Chemoembolization (TACE) for Treatment of HCC With Main Portal Vein Tumor Thrombus Versus TACE Alone: a Prospective Randomized Controlled Multicentre Trial
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 253

## Sources

- ClinicalTrials.gov NCT02971345: https://clinicaltrials.gov/study/NCT02971345

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Epirubicin](https://onco.cc/drugs/epirubicin/), [Ethiodized oil](https://onco.cc/drugs/ethiodized-oil/)

---
JSON: https://onco.cc/api/v1/entities/nct02971345.json